company_name,company_ticker,company_lei,company_cik,year,quarter,start_date,end_date,filing_date,parent,tag,financial_name,factor,balance,unit,value
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2013.0,Q4,2013-07-01,2013-09-30,,netincomecontinuing,netincome,Consolidated Net Income / (Loss),+,credit,usd,483802.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2013.0,Q4,2013-07-01,2013-09-30,,netcashfromcontinuingoperatingactivities,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,483802.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2013.0,Q4,2013-07-01,2013-09-30,,netcashfromcontinuingoperatingactivities,depreciationexpense,Depreciation Expense,+,debit,usd,29673.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2013.0,Q4,2013-07-01,2013-09-30,,netcashfromcontinuingoperatingactivities,amortizationexpense,Amortization Expense,+,debit,usd,-295.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2013.0,Q4,2013-07-01,2013-09-30,,netcashfromcontinuingoperatingactivities,noncashadjustmentstonetincome,Non-Cash Adjustments To Reconcile Net Income,+,debit,usd,3001413.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2013.0,Q4,2013-07-01,2013-09-30,,netcashfromcontinuingoperatingactivities,increasedecreaseinoperatingcapital,"Changes in Operating Assets and Liabilities, net",+,debit,usd,-3830006.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2013.0,Q4,2013-07-01,2013-09-30,,netcashfromoperatingactivities,netcashfromcontinuingoperatingactivities,Net Cash From Continuing Operating Activities,+,debit,usd,-315413.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2013.0,Q4,2013-07-01,2013-09-30,,netchangeincash,netcashfromoperatingactivities,Net Cash From Operating Activities,+,debit,usd,-315413.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2013.0,Q4,2013-07-01,2013-09-30,,netcashfromcontinuinginvestingactivities,purchaseofplantpropertyandequipment,"Purchase of Property, Plant & Equipment",+,debit,usd,-10325.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2013.0,Q4,2013-07-01,2013-09-30,,netcashfrominvestingactivities,netcashfromcontinuinginvestingactivities,Net Cash From Continuing Investing Activities,+,debit,usd,-10325.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2013.0,Q4,2013-07-01,2013-09-30,,netchangeincash,netcashfrominvestingactivities,Net Cash From Investing Activities,+,debit,usd,-10325.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2013.0,Q4,2013-07-01,2013-09-30,,netcashfromcontinuingfinancingactivities,issuanceofdebt,Issuance of Debt,+,debit,usd,0.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2013.0,Q4,2013-07-01,2013-09-30,,netcashfromcontinuingfinancingactivities,issuanceofpreferredequity,Issuance of Preferred Equity,+,debit,usd,0.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2013.0,Q4,2013-07-01,2013-09-30,,netcashfromcontinuingfinancingactivities,otherfinancingactivitiesnet,"Other Financing Activities, net",+,debit,usd,0.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2013.0,Q4,2013-07-01,2013-09-30,,netchangeincash,netcashfromfinancingactivities,Net Cash From Financing Activities,+,debit,usd,-19737.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2013.0,Q4,2013-07-01,2013-09-30,,,netchangeincash,Net Change in Cash & Equivalents,=,debit,usd,-345475.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q1,2013-10-01,2013-12-31,2015-02-17 16:05:43+00:00,netincomecontinuing,netincome,Consolidated Net Income / (Loss),+,credit,usd,-3255000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q1,2013-10-01,2013-12-31,2015-02-17 16:05:43+00:00,netcashfromcontinuingoperatingactivities,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-3255000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q1,2013-10-01,2013-12-31,2015-02-17 16:05:43+00:00,netcashfromcontinuingoperatingactivities,depreciationexpense,Depreciation Expense,+,debit,usd,31000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q1,2013-10-01,2013-12-31,2015-02-17 16:05:43+00:00,netcashfromcontinuingoperatingactivities,noncashadjustmentstonetincome,Non-Cash Adjustments To Reconcile Net Income,+,debit,usd,1803000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q1,2013-10-01,2013-12-31,2015-02-17 16:05:43+00:00,netcashfromcontinuingoperatingactivities,increasedecreaseinoperatingcapital,"Changes in Operating Assets and Liabilities, net",+,debit,usd,1444000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q1,2013-10-01,2013-12-31,2015-02-17 16:05:43+00:00,netcashfromoperatingactivities,netcashfromcontinuingoperatingactivities,Net Cash From Continuing Operating Activities,+,debit,usd,23000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q1,2013-10-01,2013-12-31,2015-02-17 16:05:43+00:00,netchangeincash,netcashfromoperatingactivities,Net Cash From Operating Activities,+,debit,usd,23000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q1,2013-10-01,2013-12-31,2015-02-17 16:05:43+00:00,netcashfromcontinuinginvestingactivities,purchaseofplantpropertyandequipment,"Purchase of Property, Plant & Equipment",+,debit,usd,-7000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q1,2013-10-01,2013-12-31,2015-02-17 16:05:43+00:00,netcashfromcontinuinginvestingactivities,saleofinvestments,Sale and/or Maturity of Investments,+,debit,usd,0.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q1,2013-10-01,2013-12-31,2015-02-17 16:05:43+00:00,netcashfrominvestingactivities,netcashfromcontinuinginvestingactivities,Net Cash From Continuing Investing Activities,+,debit,usd,-7000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q1,2013-10-01,2013-12-31,2015-02-17 16:05:43+00:00,netchangeincash,netcashfrominvestingactivities,Net Cash From Investing Activities,+,debit,usd,-7000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q1,2013-10-01,2013-12-31,2015-02-17 16:05:43+00:00,netcashfromcontinuingfinancingactivities,otherfinancingactivitiesnet,"Other Financing Activities, net",+,debit,usd,-498000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q1,2013-10-01,2013-12-31,2015-02-17 16:05:43+00:00,netcashfromfinancingactivities,netcashfromcontinuingfinancingactivities,Net Cash From Continuing Financing Activities,+,debit,usd,-498000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q1,2013-10-01,2013-12-31,2015-02-17 16:05:43+00:00,netchangeincash,netcashfromfinancingactivities,Net Cash From Financing Activities,+,debit,usd,-498000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q1,2013-10-01,2013-12-31,2015-02-17 16:05:43+00:00,,netchangeincash,Net Change in Cash & Equivalents,=,debit,usd,-482000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q1,2013-10-01,2013-12-31,2015-02-17 16:05:43+00:00,,cashinterestpaid,Cash Interest Paid,=,,usd,0.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q4,2014-07-01,2014-09-30,,netincomecontinuing,netincome,Consolidated Net Income / (Loss),+,credit,usd,-9103448.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q4,2014-07-01,2014-09-30,,netcashfromcontinuingoperatingactivities,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-9103448.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q4,2014-07-01,2014-09-30,,netcashfromcontinuingoperatingactivities,depreciationexpense,Depreciation Expense,+,debit,usd,22238.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q4,2014-07-01,2014-09-30,,netcashfromcontinuingoperatingactivities,noncashadjustmentstonetincome,Non-Cash Adjustments To Reconcile Net Income,+,debit,usd,-564048.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q4,2014-07-01,2014-09-30,,netcashfromcontinuingoperatingactivities,increasedecreaseinoperatingcapital,"Changes in Operating Assets and Liabilities, net",+,debit,usd,2517005.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q4,2014-07-01,2014-09-30,,netcashfromoperatingactivities,netcashfromcontinuingoperatingactivities,Net Cash From Continuing Operating Activities,+,debit,usd,-7128253.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q4,2014-07-01,2014-09-30,,netchangeincash,netcashfromoperatingactivities,Net Cash From Operating Activities,+,debit,usd,-7128253.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q4,2014-07-01,2014-09-30,,netcashfromcontinuinginvestingactivities,purchaseofplantpropertyandequipment,"Purchase of Property, Plant & Equipment",+,debit,usd,-7185.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q4,2014-07-01,2014-09-30,,netcashfromcontinuinginvestingactivities,purchaseofinvestments,Purchase of Investments,+,debit,usd,-19999000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q4,2014-07-01,2014-09-30,,netcashfrominvestingactivities,netcashfromcontinuinginvestingactivities,Net Cash From Continuing Investing Activities,+,debit,usd,-20006185.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q4,2014-07-01,2014-09-30,,netchangeincash,netcashfrominvestingactivities,Net Cash From Investing Activities,+,debit,usd,-20006185.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q4,2014-07-01,2014-09-30,,netcashfromcontinuingfinancingactivities,issuanceofcommonequity,Issuance of Common Equity,+,debit,usd,0.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q4,2014-07-01,2014-09-30,,netcashfromcontinuingfinancingactivities,otherfinancingactivitiesnet,"Other Financing Activities, net",+,debit,usd,0.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q4,2014-07-01,2014-09-30,,netchangeincash,netcashfromfinancingactivities,Net Cash From Financing Activities,+,debit,usd,65083.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q4,2014-07-01,2014-09-30,,,netchangeincash,Net Change in Cash & Equivalents,=,debit,usd,-27069355.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q4,2014-07-01,2014-09-30,,,cashinterestpaid,Cash Interest Paid,=,,usd,1756.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q1,2015-01-01,2015-03-31,2016-05-10 17:08:45+00:00,netincomecontinuing,netincome,Consolidated Net Income / (Loss),+,credit,usd,19697000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q1,2015-01-01,2015-03-31,2016-05-10 17:08:45+00:00,netcashfromcontinuingoperatingactivities,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,19697000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q1,2015-01-01,2015-03-31,2016-05-10 17:08:45+00:00,netcashfromcontinuingoperatingactivities,depreciationexpense,Depreciation Expense,+,debit,usd,12000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q1,2015-01-01,2015-03-31,2016-05-10 17:08:45+00:00,netcashfromcontinuingoperatingactivities,amortizationexpense,Amortization Expense,+,debit,usd,0.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q1,2015-01-01,2015-03-31,2016-05-10 17:08:45+00:00,netcashfromcontinuingoperatingactivities,noncashadjustmentstonetincome,Non-Cash Adjustments To Reconcile Net Income,+,debit,usd,957000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q1,2015-01-01,2015-03-31,2016-05-10 17:08:45+00:00,netcashfromcontinuingoperatingactivities,increasedecreaseinoperatingcapital,"Changes in Operating Assets and Liabilities, net",+,debit,usd,5170000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q1,2015-01-01,2015-03-31,2016-05-10 17:08:45+00:00,netcashfromoperatingactivities,netcashfromcontinuingoperatingactivities,Net Cash From Continuing Operating Activities,+,debit,usd,25836000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q1,2015-01-01,2015-03-31,2016-05-10 17:08:45+00:00,netchangeincash,netcashfromoperatingactivities,Net Cash From Operating Activities,+,debit,usd,25836000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q1,2015-01-01,2015-03-31,2016-05-10 17:08:45+00:00,netcashfromcontinuinginvestingactivities,purchaseofplantpropertyandequipment,"Purchase of Property, Plant & Equipment",+,debit,usd,-43000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q1,2015-01-01,2015-03-31,2016-05-10 17:08:45+00:00,netcashfromcontinuinginvestingactivities,acquisitions,Acquisitions,+,debit,usd,0.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q1,2015-01-01,2015-03-31,2016-05-10 17:08:45+00:00,netcashfromcontinuinginvestingactivities,purchaseofinvestments,Purchase of Investments,+,debit,usd,-15998000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q1,2015-01-01,2015-03-31,2016-05-10 17:08:45+00:00,netcashfromcontinuinginvestingactivities,saleofplantpropertyandequipment,"Sale of Property, Plant & Equipment",+,debit,usd,0.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q1,2015-01-01,2015-03-31,2016-05-10 17:08:45+00:00,netcashfromcontinuinginvestingactivities,saleofinvestments,Sale and/or Maturity of Investments,+,debit,usd,0.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q1,2015-01-01,2015-03-31,2016-05-10 17:08:45+00:00,netcashfrominvestingactivities,netcashfromcontinuinginvestingactivities,Net Cash From Continuing Investing Activities,+,debit,usd,-16041000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q1,2015-01-01,2015-03-31,2016-05-10 17:08:45+00:00,netchangeincash,netcashfrominvestingactivities,Net Cash From Investing Activities,+,debit,usd,-16041000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q1,2015-01-01,2015-03-31,2016-05-10 17:08:45+00:00,netcashfromcontinuingfinancingactivities,issuanceofcommonequity,Issuance of Common Equity,+,debit,usd,54696000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q1,2015-01-01,2015-03-31,2016-05-10 17:08:45+00:00,netcashfromcontinuingfinancingactivities,otherfinancingactivitiesnet,"Other Financing Activities, net",+,debit,usd,564000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q1,2015-01-01,2015-03-31,2016-05-10 17:08:45+00:00,netcashfromfinancingactivities,netcashfromcontinuingfinancingactivities,Net Cash From Continuing Financing Activities,+,debit,usd,55260000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q1,2015-01-01,2015-03-31,2016-05-10 17:08:45+00:00,netchangeincash,netcashfromfinancingactivities,Net Cash From Financing Activities,+,debit,usd,55260000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q1,2015-01-01,2015-03-31,2016-05-10 17:08:45+00:00,,netchangeincash,Net Change in Cash & Equivalents,=,debit,usd,65055000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q1,2015-01-01,2015-03-31,2016-05-10 17:08:45+00:00,,cashinterestpaid,Cash Interest Paid,=,,usd,1000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q1,2015-01-01,2015-03-31,2016-05-10 17:08:45+00:00,,cashincometaxespaid,Cash Income Taxes Paid,=,,usd,0.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q2,2015-04-01,2015-06-30,,netincomecontinuing,netincome,Consolidated Net Income / (Loss),+,credit,usd,-8177000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q2,2015-04-01,2015-06-30,,netcashfromcontinuingoperatingactivities,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-8177000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q2,2015-04-01,2015-06-30,,netcashfromcontinuingoperatingactivities,depreciationexpense,Depreciation Expense,+,debit,usd,10000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q2,2015-04-01,2015-06-30,,netcashfromcontinuingoperatingactivities,noncashadjustmentstonetincome,Non-Cash Adjustments To Reconcile Net Income,+,debit,usd,990000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q2,2015-04-01,2015-06-30,,netcashfromcontinuingoperatingactivities,increasedecreaseinoperatingcapital,"Changes in Operating Assets and Liabilities, net",+,debit,usd,-4943000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q2,2015-04-01,2015-06-30,,netcashfromoperatingactivities,netcashfromcontinuingoperatingactivities,Net Cash From Continuing Operating Activities,+,debit,usd,-12120000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q2,2015-04-01,2015-06-30,,netchangeincash,netcashfromoperatingactivities,Net Cash From Operating Activities,+,debit,usd,-12120000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q2,2015-04-01,2015-06-30,,netcashfromcontinuinginvestingactivities,purchaseofplantpropertyandequipment,"Purchase of Property, Plant & Equipment",+,debit,usd,-284000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q2,2015-04-01,2015-06-30,,netcashfromcontinuinginvestingactivities,purchaseofinvestments,Purchase of Investments,+,debit,usd,-74001000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q2,2015-04-01,2015-06-30,,netcashfrominvestingactivities,netcashfromcontinuinginvestingactivities,Net Cash From Continuing Investing Activities,+,debit,usd,-74285000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q2,2015-04-01,2015-06-30,,netchangeincash,netcashfrominvestingactivities,Net Cash From Investing Activities,+,debit,usd,-74285000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q2,2015-04-01,2015-06-30,,netcashfromcontinuingfinancingactivities,issuanceofcommonequity,Issuance of Common Equity,+,debit,usd,-365000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q2,2015-04-01,2015-06-30,,netcashfromcontinuingfinancingactivities,otherfinancingactivitiesnet,"Other Financing Activities, net",+,debit,usd,532000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q2,2015-04-01,2015-06-30,,netcashfromfinancingactivities,netcashfromcontinuingfinancingactivities,Net Cash From Continuing Financing Activities,+,debit,usd,167000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q2,2015-04-01,2015-06-30,,netchangeincash,netcashfromfinancingactivities,Net Cash From Financing Activities,+,debit,usd,167000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q2,2015-04-01,2015-06-30,,,netchangeincash,Net Change in Cash & Equivalents,=,debit,usd,-86238000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q2,2015-04-01,2015-06-30,,,cashinterestpaid,Cash Interest Paid,=,,usd,3000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q2,2015-04-01,2015-06-30,,,cashincometaxespaid,Cash Income Taxes Paid,=,,usd,187000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q3,2015-07-01,2015-09-30,,netincomecontinuing,netincome,Consolidated Net Income / (Loss),+,credit,usd,-10168000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q3,2015-07-01,2015-09-30,,netcashfromcontinuingoperatingactivities,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-10168000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q3,2015-07-01,2015-09-30,,netcashfromcontinuingoperatingactivities,depreciationexpense,Depreciation Expense,+,debit,usd,9000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q3,2015-07-01,2015-09-30,,netcashfromcontinuingoperatingactivities,noncashadjustmentstonetincome,Non-Cash Adjustments To Reconcile Net Income,+,debit,usd,-1849000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q3,2015-07-01,2015-09-30,,netcashfromcontinuingoperatingactivities,increasedecreaseinoperatingcapital,"Changes in Operating Assets and Liabilities, net",+,debit,usd,5373000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q3,2015-07-01,2015-09-30,,netcashfromoperatingactivities,netcashfromcontinuingoperatingactivities,Net Cash From Continuing Operating Activities,+,debit,usd,-6635000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q3,2015-07-01,2015-09-30,,netchangeincash,netcashfromoperatingactivities,Net Cash From Operating Activities,+,debit,usd,-6635000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q3,2015-07-01,2015-09-30,,netcashfromcontinuinginvestingactivities,purchaseofplantpropertyandequipment,"Purchase of Property, Plant & Equipment",+,debit,usd,-1071000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q3,2015-07-01,2015-09-30,,netcashfromcontinuinginvestingactivities,purchaseofinvestments,Purchase of Investments,+,debit,usd,-16000000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q3,2015-07-01,2015-09-30,,netcashfromcontinuinginvestingactivities,saleofinvestments,Sale and/or Maturity of Investments,+,debit,usd,81999000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q3,2015-07-01,2015-09-30,,netcashfrominvestingactivities,netcashfromcontinuinginvestingactivities,Net Cash From Continuing Investing Activities,+,debit,usd,64928000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q3,2015-07-01,2015-09-30,,netchangeincash,netcashfrominvestingactivities,Net Cash From Investing Activities,+,debit,usd,64928000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q3,2015-07-01,2015-09-30,,,netchangeincash,Net Change in Cash & Equivalents,=,debit,usd,58293000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q3,2015-07-01,2015-09-30,,,cashinterestpaid,Cash Interest Paid,=,,usd,-4000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q3,2015-07-01,2015-09-30,,,cashincometaxespaid,Cash Income Taxes Paid,=,,usd,295000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q4,2015-10-01,2015-12-31,,netincomecontinuing,netincome,Consolidated Net Income / (Loss),+,credit,usd,1219000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q4,2015-10-01,2015-12-31,,netcashfromcontinuingoperatingactivities,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,1219000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q4,2015-10-01,2015-12-31,,netcashfromcontinuingoperatingactivities,depreciationexpense,Depreciation Expense,+,debit,usd,81000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q4,2015-10-01,2015-12-31,,netcashfromcontinuingoperatingactivities,noncashadjustmentstonetincome,Non-Cash Adjustments To Reconcile Net Income,+,debit,usd,3903000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q4,2015-10-01,2015-12-31,,netcashfromcontinuingoperatingactivities,increasedecreaseinoperatingcapital,"Changes in Operating Assets and Liabilities, net",+,debit,usd,-22002000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q4,2015-10-01,2015-12-31,,netcashfromoperatingactivities,netcashfromcontinuingoperatingactivities,Net Cash From Continuing Operating Activities,+,debit,usd,-16799000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q4,2015-10-01,2015-12-31,,netchangeincash,netcashfromoperatingactivities,Net Cash From Operating Activities,+,debit,usd,-16799000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q4,2015-10-01,2015-12-31,,netcashfromcontinuinginvestingactivities,purchaseofplantpropertyandequipment,"Purchase of Property, Plant & Equipment",+,debit,usd,-483000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q4,2015-10-01,2015-12-31,,netcashfromcontinuinginvestingactivities,saleofinvestments,Sale and/or Maturity of Investments,+,debit,usd,24000000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q4,2015-10-01,2015-12-31,,netcashfrominvestingactivities,netcashfromcontinuinginvestingactivities,Net Cash From Continuing Investing Activities,+,debit,usd,23517000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q4,2015-10-01,2015-12-31,,netchangeincash,netcashfrominvestingactivities,Net Cash From Investing Activities,+,debit,usd,23517000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q4,2015-10-01,2015-12-31,,netcashfromcontinuingfinancingactivities,otherfinancingactivitiesnet,"Other Financing Activities, net",+,debit,usd,386000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q4,2015-10-01,2015-12-31,,netcashfromfinancingactivities,netcashfromcontinuingfinancingactivities,Net Cash From Continuing Financing Activities,+,debit,usd,386000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q4,2015-10-01,2015-12-31,,netchangeincash,netcashfromfinancingactivities,Net Cash From Financing Activities,+,debit,usd,386000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q4,2015-10-01,2015-12-31,,,netchangeincash,Net Change in Cash & Equivalents,=,debit,usd,7104000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q4,2015-10-01,2015-12-31,,,cashinterestpaid,Cash Interest Paid,=,,usd,11000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q1,2016-01-01,2016-03-31,2017-05-08 17:30:45+00:00,netincomecontinuing,netincome,Consolidated Net Income / (Loss),+,credit,usd,-896000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q1,2016-01-01,2016-03-31,2017-05-08 17:30:45+00:00,netcashfromcontinuingoperatingactivities,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-896000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q1,2016-01-01,2016-03-31,2017-05-08 17:30:45+00:00,netcashfromcontinuingoperatingactivities,depreciationexpense,Depreciation Expense,+,debit,usd,140000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q1,2016-01-01,2016-03-31,2017-05-08 17:30:45+00:00,netcashfromcontinuingoperatingactivities,amortizationexpense,Amortization Expense,+,debit,usd,104000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q1,2016-01-01,2016-03-31,2017-05-08 17:30:45+00:00,netcashfromcontinuingoperatingactivities,noncashadjustmentstonetincome,Non-Cash Adjustments To Reconcile Net Income,+,debit,usd,936000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q1,2016-01-01,2016-03-31,2017-05-08 17:30:45+00:00,netcashfromcontinuingoperatingactivities,increasedecreaseinoperatingcapital,"Changes in Operating Assets and Liabilities, net",+,debit,usd,2824000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q1,2016-01-01,2016-03-31,2017-05-08 17:30:45+00:00,netcashfromoperatingactivities,netcashfromcontinuingoperatingactivities,Net Cash From Continuing Operating Activities,+,debit,usd,3108000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q1,2016-01-01,2016-03-31,2017-05-08 17:30:45+00:00,netchangeincash,netcashfromoperatingactivities,Net Cash From Operating Activities,+,debit,usd,3108000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q1,2016-01-01,2016-03-31,2017-05-08 17:30:45+00:00,netcashfromcontinuinginvestingactivities,purchaseofplantpropertyandequipment,"Purchase of Property, Plant & Equipment",+,debit,usd,-804000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q1,2016-01-01,2016-03-31,2017-05-08 17:30:45+00:00,netcashfromcontinuinginvestingactivities,acquisitions,Acquisitions,+,debit,usd,-4850000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q1,2016-01-01,2016-03-31,2017-05-08 17:30:45+00:00,netcashfromcontinuinginvestingactivities,purchaseofinvestments,Purchase of Investments,+,debit,usd,-62000000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q1,2016-01-01,2016-03-31,2017-05-08 17:30:45+00:00,netcashfromcontinuinginvestingactivities,saleofplantpropertyandequipment,"Sale of Property, Plant & Equipment",+,debit,usd,1750000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q1,2016-01-01,2016-03-31,2017-05-08 17:30:45+00:00,netcashfromcontinuinginvestingactivities,saleofinvestments,Sale and/or Maturity of Investments,+,debit,usd,62000000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q1,2016-01-01,2016-03-31,2017-05-08 17:30:45+00:00,netcashfrominvestingactivities,netcashfromcontinuinginvestingactivities,Net Cash From Continuing Investing Activities,+,debit,usd,-3904000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q1,2016-01-01,2016-03-31,2017-05-08 17:30:45+00:00,netchangeincash,netcashfrominvestingactivities,Net Cash From Investing Activities,+,debit,usd,-3904000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q1,2016-01-01,2016-03-31,2017-05-08 17:30:45+00:00,netcashfromcontinuingfinancingactivities,repaymentofdebt,Repayment of Debt,+,debit,usd,0.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q1,2016-01-01,2016-03-31,2017-05-08 17:30:45+00:00,netcashfromcontinuingfinancingactivities,repurchaseofcommonequity,Repurchase of Common Equity,+,debit,usd,0.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q1,2016-01-01,2016-03-31,2017-05-08 17:30:45+00:00,netcashfromcontinuingfinancingactivities,otherfinancingactivitiesnet,"Other Financing Activities, net",+,debit,usd,0.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q1,2016-01-01,2016-03-31,2017-05-08 17:30:45+00:00,netchangeincash,netcashfromfinancingactivities,Net Cash From Financing Activities,+,debit,usd,0.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q1,2016-01-01,2016-03-31,2017-05-08 17:30:45+00:00,,netchangeincash,Net Change in Cash & Equivalents,=,debit,usd,-796000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q2,2016-04-01,2016-06-30,,netincomecontinuing,netincome,Consolidated Net Income / (Loss),+,credit,usd,13098000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q2,2016-04-01,2016-06-30,,netcashfromcontinuingoperatingactivities,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,13098000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q2,2016-04-01,2016-06-30,,netcashfromcontinuingoperatingactivities,depreciationexpense,Depreciation Expense,+,debit,usd,156000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q2,2016-04-01,2016-06-30,,netcashfromcontinuingoperatingactivities,amortizationexpense,Amortization Expense,+,debit,usd,156000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q2,2016-04-01,2016-06-30,,netcashfromcontinuingoperatingactivities,noncashadjustmentstonetincome,Non-Cash Adjustments To Reconcile Net Income,+,debit,usd,2922000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q2,2016-04-01,2016-06-30,,netcashfromcontinuingoperatingactivities,increasedecreaseinoperatingcapital,"Changes in Operating Assets and Liabilities, net",+,debit,usd,-18956000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q2,2016-04-01,2016-06-30,,netcashfromoperatingactivities,netcashfromcontinuingoperatingactivities,Net Cash From Continuing Operating Activities,+,debit,usd,-2624000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q2,2016-04-01,2016-06-30,,netchangeincash,netcashfromoperatingactivities,Net Cash From Operating Activities,+,debit,usd,-2624000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q2,2016-04-01,2016-06-30,,netcashfromcontinuinginvestingactivities,purchaseofplantpropertyandequipment,"Purchase of Property, Plant & Equipment",+,debit,usd,-100000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q2,2016-04-01,2016-06-30,,netcashfrominvestingactivities,netcashfromcontinuinginvestingactivities,Net Cash From Continuing Investing Activities,+,debit,usd,-100000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q2,2016-04-01,2016-06-30,,netchangeincash,netcashfrominvestingactivities,Net Cash From Investing Activities,+,debit,usd,-100000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q2,2016-04-01,2016-06-30,,,netchangeincash,Net Change in Cash & Equivalents,=,debit,usd,-2724000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q3,2016-07-01,2016-09-30,,netincomecontinuing,netincome,Consolidated Net Income / (Loss),+,credit,usd,11950000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q3,2016-07-01,2016-09-30,,netcashfromcontinuingoperatingactivities,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,11950000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q3,2016-07-01,2016-09-30,,netcashfromcontinuingoperatingactivities,depreciationexpense,Depreciation Expense,+,debit,usd,165000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q3,2016-07-01,2016-09-30,,netcashfromcontinuingoperatingactivities,amortizationexpense,Amortization Expense,+,debit,usd,201000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q3,2016-07-01,2016-09-30,,netcashfromcontinuingoperatingactivities,noncashadjustmentstonetincome,Non-Cash Adjustments To Reconcile Net Income,+,debit,usd,-1782000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q3,2016-07-01,2016-09-30,,netcashfromcontinuingoperatingactivities,increasedecreaseinoperatingcapital,"Changes in Operating Assets and Liabilities, net",+,debit,usd,2634000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q3,2016-07-01,2016-09-30,,netcashfromoperatingactivities,netcashfromcontinuingoperatingactivities,Net Cash From Continuing Operating Activities,+,debit,usd,13168000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q3,2016-07-01,2016-09-30,,netchangeincash,netcashfromoperatingactivities,Net Cash From Operating Activities,+,debit,usd,13168000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q3,2016-07-01,2016-09-30,,netcashfromcontinuinginvestingactivities,purchaseofplantpropertyandequipment,"Purchase of Property, Plant & Equipment",+,debit,usd,-179000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q3,2016-07-01,2016-09-30,,netcashfromcontinuinginvestingactivities,acquisitions,Acquisitions,+,debit,usd,-14000000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q3,2016-07-01,2016-09-30,,netcashfrominvestingactivities,netcashfromcontinuinginvestingactivities,Net Cash From Continuing Investing Activities,+,debit,usd,-14179000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q3,2016-07-01,2016-09-30,,netchangeincash,netcashfrominvestingactivities,Net Cash From Investing Activities,+,debit,usd,-14179000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q3,2016-07-01,2016-09-30,,netcashfromcontinuingfinancingactivities,repurchaseofcommonequity,Repurchase of Common Equity,+,debit,usd,-16497000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q3,2016-07-01,2016-09-30,,netcashfromcontinuingfinancingactivities,otherfinancingactivitiesnet,"Other Financing Activities, net",+,debit,usd,1256000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q3,2016-07-01,2016-09-30,,netcashfromfinancingactivities,netcashfromcontinuingfinancingactivities,Net Cash From Continuing Financing Activities,+,debit,usd,-15241000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q3,2016-07-01,2016-09-30,,netchangeincash,netcashfromfinancingactivities,Net Cash From Financing Activities,+,debit,usd,-15241000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q3,2016-07-01,2016-09-30,,,netchangeincash,Net Change in Cash & Equivalents,=,debit,usd,-16252000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q3,2016-07-01,2016-09-30,,,cashincometaxespaid,Cash Income Taxes Paid,=,,usd,2800000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q4,2016-10-01,2016-12-31,,netincomecontinuing,netincome,Consolidated Net Income / (Loss),+,credit,usd,57301000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q4,2016-10-01,2016-12-31,,netcashfromcontinuingoperatingactivities,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,57301000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q4,2016-10-01,2016-12-31,,netcashfromcontinuingoperatingactivities,depreciationexpense,Depreciation Expense,+,debit,usd,180000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q4,2016-10-01,2016-12-31,,netcashfromcontinuingoperatingactivities,amortizationexpense,Amortization Expense,+,debit,usd,487000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q4,2016-10-01,2016-12-31,,netcashfromcontinuingoperatingactivities,noncashadjustmentstonetincome,Non-Cash Adjustments To Reconcile Net Income,+,debit,usd,-3488000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q4,2016-10-01,2016-12-31,,netcashfromcontinuingoperatingactivities,increasedecreaseinoperatingcapital,"Changes in Operating Assets and Liabilities, net",+,debit,usd,-14925000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q4,2016-10-01,2016-12-31,,netcashfromoperatingactivities,netcashfromcontinuingoperatingactivities,Net Cash From Continuing Operating Activities,+,debit,usd,39555000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q4,2016-10-01,2016-12-31,,netchangeincash,netcashfromoperatingactivities,Net Cash From Operating Activities,+,debit,usd,39555000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q4,2016-10-01,2016-12-31,,netcashfromcontinuinginvestingactivities,purchaseofplantpropertyandequipment,"Purchase of Property, Plant & Equipment",+,debit,usd,-507000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q4,2016-10-01,2016-12-31,,netcashfromcontinuinginvestingactivities,acquisitions,Acquisitions,+,debit,usd,-27110000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q4,2016-10-01,2016-12-31,,netcashfrominvestingactivities,netcashfromcontinuinginvestingactivities,Net Cash From Continuing Investing Activities,+,debit,usd,-27617000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q4,2016-10-01,2016-12-31,,netchangeincash,netcashfrominvestingactivities,Net Cash From Investing Activities,+,debit,usd,-27617000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q4,2016-10-01,2016-12-31,,netcashfromcontinuingfinancingactivities,repurchaseofcommonequity,Repurchase of Common Equity,+,debit,usd,-20506000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q4,2016-10-01,2016-12-31,,netcashfromcontinuingfinancingactivities,otherfinancingactivitiesnet,"Other Financing Activities, net",+,debit,usd,2077000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q4,2016-10-01,2016-12-31,,netcashfromfinancingactivities,netcashfromcontinuingfinancingactivities,Net Cash From Continuing Financing Activities,+,debit,usd,-18429000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q4,2016-10-01,2016-12-31,,netchangeincash,netcashfromfinancingactivities,Net Cash From Financing Activities,+,debit,usd,-18429000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q4,2016-10-01,2016-12-31,,,netchangeincash,Net Change in Cash & Equivalents,=,debit,usd,-6491000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q4,2016-10-01,2016-12-31,,,cashinterestpaid,Cash Interest Paid,=,,usd,8000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:39:17+00:00,netincomecontinuing,netincome,Consolidated Net Income / (Loss),+,credit,usd,22924000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:39:17+00:00,netcashfromcontinuingoperatingactivities,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,22924000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:39:17+00:00,netcashfromcontinuingoperatingactivities,depreciationexpense,Depreciation Expense,+,debit,usd,196000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:39:17+00:00,netcashfromcontinuingoperatingactivities,amortizationexpense,Amortization Expense,+,debit,usd,712000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:39:17+00:00,netcashfromcontinuingoperatingactivities,noncashadjustmentstonetincome,Non-Cash Adjustments To Reconcile Net Income,+,debit,usd,7472000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:39:17+00:00,netcashfromcontinuingoperatingactivities,increasedecreaseinoperatingcapital,"Changes in Operating Assets and Liabilities, net",+,debit,usd,-43740000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:39:17+00:00,netcashfromoperatingactivities,netcashfromcontinuingoperatingactivities,Net Cash From Continuing Operating Activities,+,debit,usd,-12436000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:39:17+00:00,netchangeincash,netcashfromoperatingactivities,Net Cash From Operating Activities,+,debit,usd,-12436000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:39:17+00:00,netcashfromcontinuinginvestingactivities,purchaseofplantpropertyandequipment,"Purchase of Property, Plant & Equipment",+,debit,usd,-676000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:39:17+00:00,netcashfrominvestingactivities,netcashfromcontinuinginvestingactivities,Net Cash From Continuing Investing Activities,+,debit,usd,-676000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:39:17+00:00,netchangeincash,netcashfrominvestingactivities,Net Cash From Investing Activities,+,debit,usd,-676000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:39:17+00:00,netcashfromcontinuingfinancingactivities,repaymentofdebt,Repayment of Debt,+,debit,usd,-482000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:39:17+00:00,netcashfromcontinuingfinancingactivities,repurchaseofcommonequity,Repurchase of Common Equity,+,debit,usd,-13653000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:39:17+00:00,netcashfromcontinuingfinancingactivities,otherfinancingactivitiesnet,"Other Financing Activities, net",+,debit,usd,2137000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:39:17+00:00,netcashfromfinancingactivities,netcashfromcontinuingfinancingactivities,Net Cash From Continuing Financing Activities,+,debit,usd,-11998000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:39:17+00:00,netchangeincash,netcashfromfinancingactivities,Net Cash From Financing Activities,+,debit,usd,-11998000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:39:17+00:00,,netchangeincash,Net Change in Cash & Equivalents,=,debit,usd,-25110000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:39:17+00:00,,cashinterestpaid,Cash Interest Paid,=,,usd,0.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:39:17+00:00,,cashincometaxespaid,Cash Income Taxes Paid,=,,usd,0.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q2,2017-04-01,2017-06-30,,netincomecontinuing,netincome,Consolidated Net Income / (Loss),+,credit,usd,4503000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q2,2017-04-01,2017-06-30,,netcashfromcontinuingoperatingactivities,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,4503000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q2,2017-04-01,2017-06-30,,netcashfromcontinuingoperatingactivities,depreciationexpense,Depreciation Expense,+,debit,usd,236000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q2,2017-04-01,2017-06-30,,netcashfromcontinuingoperatingactivities,amortizationexpense,Amortization Expense,+,debit,usd,777000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q2,2017-04-01,2017-06-30,,netcashfromcontinuingoperatingactivities,noncashadjustmentstonetincome,Non-Cash Adjustments To Reconcile Net Income,+,debit,usd,111000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q2,2017-04-01,2017-06-30,,netcashfromcontinuingoperatingactivities,increasedecreaseinoperatingcapital,"Changes in Operating Assets and Liabilities, net",+,debit,usd,31921000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q2,2017-04-01,2017-06-30,,netcashfromoperatingactivities,netcashfromcontinuingoperatingactivities,Net Cash From Continuing Operating Activities,+,debit,usd,37548000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q2,2017-04-01,2017-06-30,,netchangeincash,netcashfromoperatingactivities,Net Cash From Operating Activities,+,debit,usd,37548000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q2,2017-04-01,2017-06-30,,netcashfromcontinuinginvestingactivities,purchaseofplantpropertyandequipment,"Purchase of Property, Plant & Equipment",+,debit,usd,-208000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q2,2017-04-01,2017-06-30,,netcashfrominvestingactivities,netcashfromcontinuinginvestingactivities,Net Cash From Continuing Investing Activities,+,debit,usd,-208000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q2,2017-04-01,2017-06-30,,netchangeincash,netcashfrominvestingactivities,Net Cash From Investing Activities,+,debit,usd,-208000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q2,2017-04-01,2017-06-30,,netcashfromcontinuingfinancingactivities,repurchaseofcommonequity,Repurchase of Common Equity,+,debit,usd,-11658000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q2,2017-04-01,2017-06-30,,netcashfromcontinuingfinancingactivities,otherfinancingactivitiesnet,"Other Financing Activities, net",+,debit,usd,1993000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q2,2017-04-01,2017-06-30,,netcashfromfinancingactivities,netcashfromcontinuingfinancingactivities,Net Cash From Continuing Financing Activities,+,debit,usd,-9665000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q2,2017-04-01,2017-06-30,,netchangeincash,netcashfromfinancingactivities,Net Cash From Financing Activities,+,debit,usd,-9665000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q2,2017-04-01,2017-06-30,,,netchangeincash,Net Change in Cash & Equivalents,=,debit,usd,27675000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q2,2017-04-01,2017-06-30,,,cashincometaxespaid,Cash Income Taxes Paid,=,,usd,5585000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q3,2017-07-01,2017-09-30,,netincomecontinuing,netincome,Consolidated Net Income / (Loss),+,credit,usd,15431000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q3,2017-07-01,2017-09-30,,netcashfromcontinuingoperatingactivities,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,15431000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q3,2017-07-01,2017-09-30,,netcashfromcontinuingoperatingactivities,depreciationexpense,Depreciation Expense,+,debit,usd,225000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q3,2017-07-01,2017-09-30,,netcashfromcontinuingoperatingactivities,amortizationexpense,Amortization Expense,+,debit,usd,774000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q3,2017-07-01,2017-09-30,,netcashfromcontinuingoperatingactivities,noncashadjustmentstonetincome,Non-Cash Adjustments To Reconcile Net Income,+,debit,usd,14497000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q3,2017-07-01,2017-09-30,,netcashfromcontinuingoperatingactivities,increasedecreaseinoperatingcapital,"Changes in Operating Assets and Liabilities, net",+,debit,usd,-23041000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q3,2017-07-01,2017-09-30,,netcashfromoperatingactivities,netcashfromcontinuingoperatingactivities,Net Cash From Continuing Operating Activities,+,debit,usd,7886000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q3,2017-07-01,2017-09-30,,netchangeincash,netcashfromoperatingactivities,Net Cash From Operating Activities,+,debit,usd,7886000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q3,2017-07-01,2017-09-30,,netcashfromcontinuinginvestingactivities,purchaseofplantpropertyandequipment,"Purchase of Property, Plant & Equipment",+,debit,usd,-822000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q3,2017-07-01,2017-09-30,,netcashfromcontinuinginvestingactivities,acquisitions,Acquisitions,+,debit,usd,-750000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q3,2017-07-01,2017-09-30,,netcashfrominvestingactivities,netcashfromcontinuinginvestingactivities,Net Cash From Continuing Investing Activities,+,debit,usd,-1572000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q3,2017-07-01,2017-09-30,,netchangeincash,netcashfrominvestingactivities,Net Cash From Investing Activities,+,debit,usd,-1572000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q3,2017-07-01,2017-09-30,,netcashfromcontinuingfinancingactivities,repaymentofdebt,Repayment of Debt,+,debit,usd,-710000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q3,2017-07-01,2017-09-30,,netcashfromcontinuingfinancingactivities,repurchaseofcommonequity,Repurchase of Common Equity,+,debit,usd,-13479000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q3,2017-07-01,2017-09-30,,netcashfromcontinuingfinancingactivities,issuanceofdebt,Issuance of Debt,+,debit,usd,50000000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q3,2017-07-01,2017-09-30,,netcashfromcontinuingfinancingactivities,otherfinancingactivitiesnet,"Other Financing Activities, net",+,debit,usd,35000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q3,2017-07-01,2017-09-30,,netcashfromfinancingactivities,netcashfromcontinuingfinancingactivities,Net Cash From Continuing Financing Activities,+,debit,usd,35846000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q3,2017-07-01,2017-09-30,,netchangeincash,netcashfromfinancingactivities,Net Cash From Financing Activities,+,debit,usd,35846000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q3,2017-07-01,2017-09-30,,,netchangeincash,Net Change in Cash & Equivalents,=,debit,usd,42160000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q3,2017-07-01,2017-09-30,,,cashincometaxespaid,Cash Income Taxes Paid,=,,usd,3260000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q4,2017-10-01,2017-12-31,,netincomecontinuing,netincome,Consolidated Net Income / (Loss),+,credit,usd,9085000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q4,2017-10-01,2017-12-31,,netcashfromcontinuingoperatingactivities,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,9085000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q4,2017-10-01,2017-12-31,,netcashfromcontinuingoperatingactivities,depreciationexpense,Depreciation Expense,+,debit,usd,275000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q4,2017-10-01,2017-12-31,,netcashfromcontinuingoperatingactivities,amortizationexpense,Amortization Expense,+,debit,usd,774000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q4,2017-10-01,2017-12-31,,netcashfromcontinuingoperatingactivities,noncashadjustmentstonetincome,Non-Cash Adjustments To Reconcile Net Income,+,debit,usd,2577000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q4,2017-10-01,2017-12-31,,netcashfromcontinuingoperatingactivities,increasedecreaseinoperatingcapital,"Changes in Operating Assets and Liabilities, net",+,debit,usd,13210000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q4,2017-10-01,2017-12-31,,netcashfromoperatingactivities,netcashfromcontinuingoperatingactivities,Net Cash From Continuing Operating Activities,+,debit,usd,25921000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q4,2017-10-01,2017-12-31,,netchangeincash,netcashfromoperatingactivities,Net Cash From Operating Activities,+,debit,usd,25921000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q4,2017-10-01,2017-12-31,,netcashfromcontinuinginvestingactivities,purchaseofplantpropertyandequipment,"Purchase of Property, Plant & Equipment",+,debit,usd,-2730000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q4,2017-10-01,2017-12-31,,netcashfrominvestingactivities,netcashfromcontinuinginvestingactivities,Net Cash From Continuing Investing Activities,+,debit,usd,-2730000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q4,2017-10-01,2017-12-31,,netchangeincash,netcashfrominvestingactivities,Net Cash From Investing Activities,+,debit,usd,-2730000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q4,2017-10-01,2017-12-31,,netcashfromcontinuingfinancingactivities,repaymentofdebt,Repayment of Debt,+,debit,usd,-1250000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q4,2017-10-01,2017-12-31,,netcashfromcontinuingfinancingactivities,repurchaseofcommonequity,Repurchase of Common Equity,+,debit,usd,-5002000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q4,2017-10-01,2017-12-31,,netcashfromcontinuingfinancingactivities,otherfinancingactivitiesnet,"Other Financing Activities, net",+,debit,usd,173000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q4,2017-10-01,2017-12-31,,netcashfromfinancingactivities,netcashfromcontinuingfinancingactivities,Net Cash From Continuing Financing Activities,+,debit,usd,-6079000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q4,2017-10-01,2017-12-31,,netchangeincash,netcashfromfinancingactivities,Net Cash From Financing Activities,+,debit,usd,-6079000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q4,2017-10-01,2017-12-31,,,netchangeincash,Net Change in Cash & Equivalents,=,debit,usd,17112000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q4,2017-10-01,2017-12-31,,,cashinterestpaid,Cash Interest Paid,=,,usd,651000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q4,2017-10-01,2017-12-31,,,cashincometaxespaid,Cash Income Taxes Paid,=,,usd,1697000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 17:06:39+00:00,netincomecontinuing,netincome,Consolidated Net Income / (Loss),+,credit,usd,2616000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 17:06:39+00:00,netcashfromcontinuingoperatingactivities,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,2616000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 17:06:39+00:00,netcashfromcontinuingoperatingactivities,depreciationexpense,Depreciation Expense,+,debit,usd,341000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 17:06:39+00:00,netcashfromcontinuingoperatingactivities,amortizationexpense,Amortization Expense,+,debit,usd,764000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 17:06:39+00:00,netcashfromcontinuingoperatingactivities,noncashadjustmentstonetincome,Non-Cash Adjustments To Reconcile Net Income,+,debit,usd,6823000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 17:06:39+00:00,netcashfromcontinuingoperatingactivities,increasedecreaseinoperatingcapital,"Changes in Operating Assets and Liabilities, net",+,debit,usd,-5623000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 17:06:39+00:00,netcashfromoperatingactivities,netcashfromcontinuingoperatingactivities,Net Cash From Continuing Operating Activities,+,debit,usd,4921000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 17:06:39+00:00,netchangeincash,netcashfromoperatingactivities,Net Cash From Operating Activities,+,debit,usd,4921000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 17:06:39+00:00,netcashfromcontinuinginvestingactivities,purchaseofplantpropertyandequipment,"Purchase of Property, Plant & Equipment",+,debit,usd,-19000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 17:06:39+00:00,netcashfrominvestingactivities,netcashfromcontinuinginvestingactivities,Net Cash From Continuing Investing Activities,+,debit,usd,-19000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 17:06:39+00:00,netchangeincash,netcashfrominvestingactivities,Net Cash From Investing Activities,+,debit,usd,-19000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 17:06:39+00:00,netcashfromcontinuingfinancingactivities,repaymentofdebt,Repayment of Debt,+,debit,usd,0.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 17:06:39+00:00,netcashfromcontinuingfinancingactivities,repurchaseofcommonequity,Repurchase of Common Equity,+,debit,usd,-7003000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 17:06:39+00:00,netcashfromcontinuingfinancingactivities,otherfinancingactivitiesnet,"Other Financing Activities, net",+,debit,usd,-16886000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 17:06:39+00:00,netcashfromfinancingactivities,netcashfromcontinuingfinancingactivities,Net Cash From Continuing Financing Activities,+,debit,usd,-23889000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 17:06:39+00:00,netchangeincash,netcashfromfinancingactivities,Net Cash From Financing Activities,+,debit,usd,-23889000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 17:06:39+00:00,,netchangeincash,Net Change in Cash & Equivalents,=,debit,usd,-18987000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 17:06:39+00:00,,cashinterestpaid,Cash Interest Paid,=,,usd,368000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 17:06:39+00:00,,cashincometaxespaid,Cash Income Taxes Paid,=,,usd,96000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q2,2018-04-01,2018-06-30,,netincomecontinuing,netincome,Consolidated Net Income / (Loss),+,credit,usd,2659000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q2,2018-04-01,2018-06-30,,netcashfromcontinuingoperatingactivities,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,2659000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q2,2018-04-01,2018-06-30,,netcashfromcontinuingoperatingactivities,depreciationexpense,Depreciation Expense,+,debit,usd,342000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q2,2018-04-01,2018-06-30,,netcashfromcontinuingoperatingactivities,amortizationexpense,Amortization Expense,+,debit,usd,740000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q2,2018-04-01,2018-06-30,,netcashfromcontinuingoperatingactivities,noncashadjustmentstonetincome,Non-Cash Adjustments To Reconcile Net Income,+,debit,usd,1004000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q2,2018-04-01,2018-06-30,,netcashfromcontinuingoperatingactivities,increasedecreaseinoperatingcapital,"Changes in Operating Assets and Liabilities, net",+,debit,usd,922000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q2,2018-04-01,2018-06-30,,netcashfromoperatingactivities,netcashfromcontinuingoperatingactivities,Net Cash From Continuing Operating Activities,+,debit,usd,5667000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q2,2018-04-01,2018-06-30,,netchangeincash,netcashfromoperatingactivities,Net Cash From Operating Activities,+,debit,usd,5667000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q2,2018-04-01,2018-06-30,,netcashfromcontinuingfinancingactivities,repaymentofdebt,Repayment of Debt,+,debit,usd,-1250000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q2,2018-04-01,2018-06-30,,netcashfromcontinuingfinancingactivities,repurchaseofcommonequity,Repurchase of Common Equity,+,debit,usd,-3516000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q2,2018-04-01,2018-06-30,,netcashfromcontinuingfinancingactivities,otherfinancingactivitiesnet,"Other Financing Activities, net",+,debit,usd,3676000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q2,2018-04-01,2018-06-30,,netcashfromfinancingactivities,netcashfromcontinuingfinancingactivities,Net Cash From Continuing Financing Activities,+,debit,usd,-1090000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q2,2018-04-01,2018-06-30,,netchangeincash,netcashfromfinancingactivities,Net Cash From Financing Activities,+,debit,usd,-1090000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q2,2018-04-01,2018-06-30,,,netchangeincash,Net Change in Cash & Equivalents,=,debit,usd,4577000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q2,2018-04-01,2018-06-30,,,cashinterestpaid,Cash Interest Paid,=,,usd,161000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q2,2018-04-01,2018-06-30,,,cashincometaxespaid,Cash Income Taxes Paid,=,,usd,1735000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q3,2018-07-01,2018-09-30,,netincomecontinuing,netincome,Consolidated Net Income / (Loss),+,credit,usd,14038000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q3,2018-07-01,2018-09-30,,netcashfromcontinuingoperatingactivities,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,14038000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q3,2018-07-01,2018-09-30,,netcashfromcontinuingoperatingactivities,depreciationexpense,Depreciation Expense,+,debit,usd,235000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q3,2018-07-01,2018-09-30,,netcashfromcontinuingoperatingactivities,amortizationexpense,Amortization Expense,+,debit,usd,694000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q3,2018-07-01,2018-09-30,,netcashfromcontinuingoperatingactivities,noncashadjustmentstonetincome,Non-Cash Adjustments To Reconcile Net Income,+,debit,usd,9451000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q3,2018-07-01,2018-09-30,,netcashfromcontinuingoperatingactivities,increasedecreaseinoperatingcapital,"Changes in Operating Assets and Liabilities, net",+,debit,usd,-20730000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q3,2018-07-01,2018-09-30,,netcashfromoperatingactivities,netcashfromcontinuingoperatingactivities,Net Cash From Continuing Operating Activities,+,debit,usd,3688000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q3,2018-07-01,2018-09-30,,netchangeincash,netcashfromoperatingactivities,Net Cash From Operating Activities,+,debit,usd,3688000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q3,2018-07-01,2018-09-30,,netcashfromcontinuinginvestingactivities,purchaseofplantpropertyandequipment,"Purchase of Property, Plant & Equipment",+,debit,usd,-33000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q3,2018-07-01,2018-09-30,,netcashfrominvestingactivities,netcashfromcontinuinginvestingactivities,Net Cash From Continuing Investing Activities,+,debit,usd,-33000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q3,2018-07-01,2018-09-30,,netchangeincash,netcashfrominvestingactivities,Net Cash From Investing Activities,+,debit,usd,-33000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q3,2018-07-01,2018-09-30,,netcashfromcontinuingfinancingactivities,repaymentofdebt,Repayment of Debt,+,debit,usd,-2500000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q3,2018-07-01,2018-09-30,,netcashfromcontinuingfinancingactivities,repurchaseofcommonequity,Repurchase of Common Equity,+,debit,usd,-12109000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q3,2018-07-01,2018-09-30,,netcashfromcontinuingfinancingactivities,otherfinancingactivitiesnet,"Other Financing Activities, net",+,debit,usd,1933000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q3,2018-07-01,2018-09-30,,netcashfromfinancingactivities,netcashfromcontinuingfinancingactivities,Net Cash From Continuing Financing Activities,+,debit,usd,-12676000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q3,2018-07-01,2018-09-30,,netchangeincash,netcashfromfinancingactivities,Net Cash From Financing Activities,+,debit,usd,-12676000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q3,2018-07-01,2018-09-30,,,netchangeincash,Net Change in Cash & Equivalents,=,debit,usd,-9021000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q3,2018-07-01,2018-09-30,,,cashinterestpaid,Cash Interest Paid,=,,usd,1011000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q3,2018-07-01,2018-09-30,,,cashincometaxespaid,Cash Income Taxes Paid,=,,usd,56000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q4,2018-10-01,2018-12-31,,netincomecontinuing,netincome,Consolidated Net Income / (Loss),+,credit,usd,12590000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q4,2018-10-01,2018-12-31,,netcashfromcontinuingoperatingactivities,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,12590000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q4,2018-10-01,2018-12-31,,netcashfromcontinuingoperatingactivities,depreciationexpense,Depreciation Expense,+,debit,usd,237000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q4,2018-10-01,2018-12-31,,netcashfromcontinuingoperatingactivities,amortizationexpense,Amortization Expense,+,debit,usd,693000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q4,2018-10-01,2018-12-31,,netcashfromcontinuingoperatingactivities,noncashadjustmentstonetincome,Non-Cash Adjustments To Reconcile Net Income,+,debit,usd,15115000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q4,2018-10-01,2018-12-31,,netcashfromcontinuingoperatingactivities,increasedecreaseinoperatingcapital,"Changes in Operating Assets and Liabilities, net",+,debit,usd,9473000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q4,2018-10-01,2018-12-31,,netcashfromoperatingactivities,netcashfromcontinuingoperatingactivities,Net Cash From Continuing Operating Activities,+,debit,usd,38108000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q4,2018-10-01,2018-12-31,,netchangeincash,netcashfromoperatingactivities,Net Cash From Operating Activities,+,debit,usd,38108000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q4,2018-10-01,2018-12-31,,netcashfromcontinuinginvestingactivities,purchaseofplantpropertyandequipment,"Purchase of Property, Plant & Equipment",+,debit,usd,-81000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q4,2018-10-01,2018-12-31,,netcashfrominvestingactivities,netcashfromcontinuinginvestingactivities,Net Cash From Continuing Investing Activities,+,debit,usd,-81000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q4,2018-10-01,2018-12-31,,netchangeincash,netcashfrominvestingactivities,Net Cash From Investing Activities,+,debit,usd,-81000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q4,2018-10-01,2018-12-31,,netcashfromcontinuingfinancingactivities,repurchaseofcommonequity,Repurchase of Common Equity,+,debit,usd,-50477000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q4,2018-10-01,2018-12-31,,netcashfromcontinuingfinancingactivities,otherfinancingactivitiesnet,"Other Financing Activities, net",+,debit,usd,15000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q4,2018-10-01,2018-12-31,,netcashfromfinancingactivities,netcashfromcontinuingfinancingactivities,Net Cash From Continuing Financing Activities,+,debit,usd,-50462000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q4,2018-10-01,2018-12-31,,netchangeincash,netcashfromfinancingactivities,Net Cash From Financing Activities,+,debit,usd,-50462000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q4,2018-10-01,2018-12-31,,,netchangeincash,Net Change in Cash & Equivalents,=,debit,usd,-12435000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q4,2018-10-01,2018-12-31,,,cashinterestpaid,Cash Interest Paid,=,,usd,544000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q4,2018-10-01,2018-12-31,,,cashincometaxespaid,Cash Income Taxes Paid,=,,usd,394000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 17:09:05+00:00,netincomecontinuing,netincome,Consolidated Net Income / (Loss),+,credit,usd,8973000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 17:09:05+00:00,netcashfromcontinuingoperatingactivities,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,8973000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 17:09:05+00:00,netcashfromcontinuingoperatingactivities,depreciationexpense,Depreciation Expense,+,debit,usd,503000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 17:09:05+00:00,netcashfromcontinuingoperatingactivities,amortizationexpense,Amortization Expense,+,debit,usd,724000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 17:09:05+00:00,netcashfromcontinuingoperatingactivities,noncashadjustmentstonetincome,Non-Cash Adjustments To Reconcile Net Income,+,debit,usd,10150000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 17:09:05+00:00,netcashfromcontinuingoperatingactivities,increasedecreaseinoperatingcapital,"Changes in Operating Assets and Liabilities, net",+,debit,usd,5831000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 17:09:05+00:00,netcashfromoperatingactivities,netcashfromcontinuingoperatingactivities,Net Cash From Continuing Operating Activities,+,debit,usd,26181000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 17:09:05+00:00,netchangeincash,netcashfromoperatingactivities,Net Cash From Operating Activities,+,debit,usd,26181000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 17:09:05+00:00,netcashfromcontinuinginvestingactivities,purchaseofplantpropertyandequipment,"Purchase of Property, Plant & Equipment",+,debit,usd,-177000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 17:09:05+00:00,netcashfromcontinuinginvestingactivities,purchaseofinvestments,Purchase of Investments,+,debit,usd,0.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 17:09:05+00:00,netcashfrominvestingactivities,netcashfromcontinuinginvestingactivities,Net Cash From Continuing Investing Activities,+,debit,usd,-177000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 17:09:05+00:00,netchangeincash,netcashfrominvestingactivities,Net Cash From Investing Activities,+,debit,usd,-177000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 17:09:05+00:00,netcashfromcontinuingfinancingactivities,repaymentofdebt,Repayment of Debt,+,debit,usd,-2500000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 17:09:05+00:00,netcashfromcontinuingfinancingactivities,repurchaseofcommonequity,Repurchase of Common Equity,+,debit,usd,0.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 17:09:05+00:00,netcashfromcontinuingfinancingactivities,issuanceofdebt,Issuance of Debt,+,debit,usd,0.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 17:09:05+00:00,netcashfromcontinuingfinancingactivities,otherfinancingactivitiesnet,"Other Financing Activities, net",+,debit,usd,-156000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 17:09:05+00:00,netcashfromfinancingactivities,netcashfromcontinuingfinancingactivities,Net Cash From Continuing Financing Activities,+,debit,usd,-2656000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 17:09:05+00:00,netchangeincash,netcashfromfinancingactivities,Net Cash From Financing Activities,+,debit,usd,-2656000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 17:09:05+00:00,,netchangeincash,Net Change in Cash & Equivalents,=,debit,usd,23348000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 17:09:05+00:00,,cashinterestpaid,Cash Interest Paid,=,,usd,625000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 17:09:05+00:00,,cashincometaxespaid,Cash Income Taxes Paid,=,,usd,-6490000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q2,2019-04-01,2019-06-30,,netincomecontinuing,netincome,Consolidated Net Income / (Loss),+,credit,usd,6725000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q2,2019-04-01,2019-06-30,,netcashfromcontinuingoperatingactivities,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,6725000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q2,2019-04-01,2019-06-30,,netcashfromcontinuingoperatingactivities,depreciationexpense,Depreciation Expense,+,debit,usd,502000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q2,2019-04-01,2019-06-30,,netcashfromcontinuingoperatingactivities,amortizationexpense,Amortization Expense,+,debit,usd,724000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q2,2019-04-01,2019-06-30,,netcashfromcontinuingoperatingactivities,noncashadjustmentstonetincome,Non-Cash Adjustments To Reconcile Net Income,+,debit,usd,5679000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q2,2019-04-01,2019-06-30,,netcashfromcontinuingoperatingactivities,increasedecreaseinoperatingcapital,"Changes in Operating Assets and Liabilities, net",+,debit,usd,8762000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q2,2019-04-01,2019-06-30,,netcashfromoperatingactivities,netcashfromcontinuingoperatingactivities,Net Cash From Continuing Operating Activities,+,debit,usd,22392000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q2,2019-04-01,2019-06-30,,netchangeincash,netcashfromoperatingactivities,Net Cash From Operating Activities,+,debit,usd,22392000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q2,2019-04-01,2019-06-30,,netcashfromcontinuinginvestingactivities,purchaseofplantpropertyandequipment,"Purchase of Property, Plant & Equipment",+,debit,usd,-166000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q2,2019-04-01,2019-06-30,,netcashfrominvestingactivities,netcashfromcontinuinginvestingactivities,Net Cash From Continuing Investing Activities,+,debit,usd,-166000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q2,2019-04-01,2019-06-30,,netchangeincash,netcashfrominvestingactivities,Net Cash From Investing Activities,+,debit,usd,-166000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q2,2019-04-01,2019-06-30,,netcashfromcontinuingfinancingactivities,repaymentofdebt,Repayment of Debt,+,debit,usd,-1250000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q2,2019-04-01,2019-06-30,,netcashfromcontinuingfinancingactivities,repurchaseofcommonequity,Repurchase of Common Equity,+,debit,usd,-15000000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q2,2019-04-01,2019-06-30,,netcashfromcontinuingfinancingactivities,otherfinancingactivitiesnet,"Other Financing Activities, net",+,debit,usd,13000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q2,2019-04-01,2019-06-30,,netcashfromfinancingactivities,netcashfromcontinuingfinancingactivities,Net Cash From Continuing Financing Activities,+,debit,usd,-16237000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q2,2019-04-01,2019-06-30,,netchangeincash,netcashfromfinancingactivities,Net Cash From Financing Activities,+,debit,usd,-16237000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q2,2019-04-01,2019-06-30,,,netchangeincash,Net Change in Cash & Equivalents,=,debit,usd,5989000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q2,2019-04-01,2019-06-30,,,cashinterestpaid,Cash Interest Paid,=,,usd,596000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q2,2019-04-01,2019-06-30,,,cashincometaxespaid,Cash Income Taxes Paid,=,,usd,9364000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q3,2019-07-01,2019-09-30,,netincomecontinuing,netincome,Consolidated Net Income / (Loss),+,credit,usd,-2390000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q3,2019-07-01,2019-09-30,,netcashfromcontinuingoperatingactivities,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-2390000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q3,2019-07-01,2019-09-30,,netcashfromcontinuingoperatingactivities,depreciationexpense,Depreciation Expense,+,debit,usd,474000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q3,2019-07-01,2019-09-30,,netcashfromcontinuingoperatingactivities,amortizationexpense,Amortization Expense,+,debit,usd,724000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q3,2019-07-01,2019-09-30,,netcashfromcontinuingoperatingactivities,noncashadjustmentstonetincome,Non-Cash Adjustments To Reconcile Net Income,+,debit,usd,733000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q3,2019-07-01,2019-09-30,,netcashfromcontinuingoperatingactivities,increasedecreaseinoperatingcapital,"Changes in Operating Assets and Liabilities, net",+,debit,usd,11073000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q3,2019-07-01,2019-09-30,,netcashfromoperatingactivities,netcashfromcontinuingoperatingactivities,Net Cash From Continuing Operating Activities,+,debit,usd,10614000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q3,2019-07-01,2019-09-30,,netchangeincash,netcashfromoperatingactivities,Net Cash From Operating Activities,+,debit,usd,10614000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q3,2019-07-01,2019-09-30,,netcashfromcontinuinginvestingactivities,purchaseofplantpropertyandequipment,"Purchase of Property, Plant & Equipment",+,debit,usd,-304000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q3,2019-07-01,2019-09-30,,netcashfrominvestingactivities,netcashfromcontinuinginvestingactivities,Net Cash From Continuing Investing Activities,+,debit,usd,-304000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q3,2019-07-01,2019-09-30,,netchangeincash,netcashfrominvestingactivities,Net Cash From Investing Activities,+,debit,usd,-304000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q3,2019-07-01,2019-09-30,,netcashfromcontinuingfinancingactivities,repaymentofdebt,Repayment of Debt,+,debit,usd,-1250000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q3,2019-07-01,2019-09-30,,netcashfromcontinuingfinancingactivities,otherfinancingactivitiesnet,"Other Financing Activities, net",+,debit,usd,23000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q3,2019-07-01,2019-09-30,,netcashfromfinancingactivities,netcashfromcontinuingfinancingactivities,Net Cash From Continuing Financing Activities,+,debit,usd,-1227000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q3,2019-07-01,2019-09-30,,netchangeincash,netcashfromfinancingactivities,Net Cash From Financing Activities,+,debit,usd,-1227000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q3,2019-07-01,2019-09-30,,,netchangeincash,Net Change in Cash & Equivalents,=,debit,usd,9083000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q3,2019-07-01,2019-09-30,,,cashinterestpaid,Cash Interest Paid,=,,usd,566000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q3,2019-07-01,2019-09-30,,,cashincometaxespaid,Cash Income Taxes Paid,=,,usd,3713000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q4,2019-10-01,2019-12-31,,netincomecontinuing,netincome,Consolidated Net Income / (Loss),+,credit,usd,1005000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q4,2019-10-01,2019-12-31,,netcashfromcontinuingoperatingactivities,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,1005000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q4,2019-10-01,2019-12-31,,netcashfromcontinuingoperatingactivities,depreciationexpense,Depreciation Expense,+,debit,usd,652000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q4,2019-10-01,2019-12-31,,netcashfromcontinuingoperatingactivities,amortizationexpense,Amortization Expense,+,debit,usd,828000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q4,2019-10-01,2019-12-31,,netcashfromcontinuingoperatingactivities,noncashadjustmentstonetincome,Non-Cash Adjustments To Reconcile Net Income,+,debit,usd,595000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q4,2019-10-01,2019-12-31,,netcashfromcontinuingoperatingactivities,increasedecreaseinoperatingcapital,"Changes in Operating Assets and Liabilities, net",+,debit,usd,-6281000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q4,2019-10-01,2019-12-31,,netcashfromoperatingactivities,netcashfromcontinuingoperatingactivities,Net Cash From Continuing Operating Activities,+,debit,usd,-3201000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q4,2019-10-01,2019-12-31,,netchangeincash,netcashfromoperatingactivities,Net Cash From Operating Activities,+,debit,usd,-3201000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q4,2019-10-01,2019-12-31,,netcashfromcontinuinginvestingactivities,purchaseofplantpropertyandequipment,"Purchase of Property, Plant & Equipment",+,debit,usd,-130000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q4,2019-10-01,2019-12-31,,netcashfrominvestingactivities,netcashfromcontinuinginvestingactivities,Net Cash From Continuing Investing Activities,+,debit,usd,-130000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q4,2019-10-01,2019-12-31,,netchangeincash,netcashfrominvestingactivities,Net Cash From Investing Activities,+,debit,usd,-130000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q4,2019-10-01,2019-12-31,,netcashfromcontinuingfinancingactivities,repaymentofdebt,Repayment of Debt,+,debit,usd,-1326000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q4,2019-10-01,2019-12-31,,netcashfromcontinuingfinancingactivities,repurchaseofcommonequity,Repurchase of Common Equity,+,debit,usd,-2961000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q4,2019-10-01,2019-12-31,,netcashfromcontinuingfinancingactivities,otherfinancingactivitiesnet,"Other Financing Activities, net",+,debit,usd,182000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q4,2019-10-01,2019-12-31,,netcashfromfinancingactivities,netcashfromcontinuingfinancingactivities,Net Cash From Continuing Financing Activities,+,debit,usd,-4105000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q4,2019-10-01,2019-12-31,,netchangeincash,netcashfromfinancingactivities,Net Cash From Financing Activities,+,debit,usd,-4105000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q4,2019-10-01,2019-12-31,,,netchangeincash,Net Change in Cash & Equivalents,=,debit,usd,-7436000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q4,2019-10-01,2019-12-31,,,cashinterestpaid,Cash Interest Paid,=,,usd,691000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q4,2019-10-01,2019-12-31,,,cashincometaxespaid,Cash Income Taxes Paid,=,,usd,86000.0
